These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6104907)

  • 41. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
    LeWitt PA
    Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
    [No Abstract]   [Full Text] [Related]  

  • 42. Bromocriptine and lisuride in Parkinson disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E
    Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on antiparkinsonian agents.
    Weiner M
    Geriatrics; 1982 Sep; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract]   [Full Text] [Related]  

  • 45. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 46. [New directions in contemporary pharmacotherapy of parkinsonism (review)].
    Kurako IuL; Volianskiĭ VE
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1401-6. PubMed ID: 6150591
    [No Abstract]   [Full Text] [Related]  

  • 47. Bromocriptine in treating mania.
    Saran BM; Acharya S
    Am J Psychiatry; 1977 Jun; 134(6):702-3. PubMed ID: 17307
    [No Abstract]   [Full Text] [Related]  

  • 48. Growth hormone and changes in the secretion of thyrotropic hormone after thyrotropin-releasing hormone (TRH): ineffectiveness of dopaminergic stimulation.
    Felt V; Nedvídková J
    Endokrinologie; 1982 Oct; 80(2):201-6. PubMed ID: 6819130
    [No Abstract]   [Full Text] [Related]  

  • 49. The pharmacology of mesulergine.
    Pfeiffer RF
    Clin Neuropharmacol; 1985; 8(1):64-72. PubMed ID: 3884151
    [No Abstract]   [Full Text] [Related]  

  • 50. [Parkinson's disease].
    Mizuno Y
    No To Shinkei; 1994 Mar; 46(3):217-27. PubMed ID: 7910751
    [No Abstract]   [Full Text] [Related]  

  • 51. Possible new mechanism for the antiparkinsonian effect of amantadine.
    Bennett VL; Juorio AV; Li XM
    J Psychiatry Neurosci; 1999 Jan; 24(1):52-3. PubMed ID: 9987209
    [No Abstract]   [Full Text] [Related]  

  • 52. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

  • 53. [The early therapy challenge].
    Reichmann H
    Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
    [No Abstract]   [Full Text] [Related]  

  • 54. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
    Richard MG; Bennett JP
    Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Bromocriptine (Parlodel) in parkinsonism].
    Pakkenberg H
    Ugeskr Laeger; 1978 May; 140(22):1297. PubMed ID: 653876
    [No Abstract]   [Full Text] [Related]  

  • 58. [Endocrine effects of bromocryptin in patients with Parkinsonism].
    Barreca T; Gianrossi R; Gallamini A; Nizzo MC; Queirolo A
    Boll Soc Ital Biol Sper; 1976 Oct; 52(19):1564-7. PubMed ID: 1037379
    [No Abstract]   [Full Text] [Related]  

  • 59. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 60. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.